

Invasive Pneumococcal Disease Quarterly Report

April-June 2011

Prepared as part of a Ministry of Health
contract for scientific services

by
Esther Lim
Helen Heffernan

July 2011

Acknowledgements

This report could not have been produced without the continued support of staff in the public health units and diagnostic microbiology laboratories throughout New Zealand who provide us with data from their regions and refer isolates to ESR.

The authors would also like to thank Julie Morgan (ESR Invasive Pathogens Laboratory) for providing serotyping data and Tim Wood (ESR Health Intelligence Team) for peer checking.

Disclaimer

This report or document (“the Report”) is given by the Institute of Environmental Science and Research Limited (“ESR”) solely for the benefit of the Ministry of Health, Public Health Service Providers and other Third party Beneficiaries as defined in the Contract between ESR and the Ministry of Health, and is strictly subject to the conditions laid out in the contract.

Neither ESR nor any of its employees makes any warranty, express or implied, or assumes any legal liability or responsibility for use of the Report or its contents by any other person or organisation

Introduction

Since 17 October 2008, invasive pneumococcal disease (IPD) has been notifiable to the local Medical Officer of Health under the Health Act 1956. In June 2008, a 7-valent pneumococcal conjugate vaccine (PCV-7), Prevenar®, was added to the New Zealand childhood immunisation schedule. Later this year, a 10-valent pneumococcal conjugate vaccine (PCV-10), Synflorix™, will replace PCV-7.

PCV-10 includes the seven serotypes in PCV-7 (4, 6B, 9V, 14, 18C, 19F, and 23F) as well as serotypes 1, 5, and 7F. The recommended schedule is four doses, given at 6 weeks, 3 months, 5 months and 15 months of age.

These quarterly reports are part of an enhanced surveillance programme to monitor the impact of PCV vaccination, including the change from PCV-7 to PCV-10, on the epidemiology of IPD in New Zealand.

Methods

The data presented in this report is based on the information recorded on EpiSurv, the national notifiable disease surveillance system, as at 6 July 2011. Any changes made to EpiSurv data by public health unit staff after this date will not be reflected in this report.

Denominator data used to determine all disease rates in this report was derived from the 2010 mid-year population estimates published by Statistics New Zealand. Rates have not been calculated where there are fewer than five notified cases in any category.

The Pearson chi-square test or, where necessary, Fisher's exact test were used to determine statistical significance. P-values <0.05 are considered to be significant at the 95% level of confidence.

Streptococcus pneumoniae isolates are serotyped at ESR by the capsular antigen reaction (Neufeld test) using the Danish system of nomenclature and sera obtained from the Statens Serum Institut. Methods have not been established at ESR to identify the strain type when only pneumococcal DNA, rather than an isolate, is available. Therefore, serotype can only be determined for culture-positive IPD cases. Serotype data for invasive isolates of *S. pneumoniae* was matched with the relevant IPD case notification.

Case definition


A case of invasive pneumococcal disease is defined as:

- the isolation of *S. pneumoniae* from CSF, blood or other normally sterile site; or
- the detection by nucleic acid amplification test of pneumococcal DNA in CSF, blood or other normally sterile site; or
- a positive newer-generation *S. pneumoniae* antigen test (i.e. Binax NOW) on CSF.

Results

There were 135 IPD cases notified in the April-June 2011 quarter (148 cases in April-June 2010). There is a distinct seasonal pattern with a peak in the July-September quarter and a trough in the January-March quarter each year (Figure 1). For the 12-month period ending 30 June 2011, the notification rate was 12.0 per 100 000 population (526 cases), compared with 14.7 per 100 000 (635 cases) for the previous 12-month period ending 30 June 2010.

Figure 1. Number of cases invasive pneumococcal disease by quarter reported, Jan 2009–Jun 2011



The distribution of IPD cases and rates by age group is presented in Table 1. For the 12-month period ending 30 June 2011, the highest rates were reported in the 65+ years (40.9 per 100 000 population, 233 cases) and the <2 years (30.8 per 100 000, 39 cases) age groups. The rates for the 12 months ending June 2011 were similar or lower than the rates in the previous 12 months for all age groups.

Table 1. Number of cases and rates of invasive pneumococcal disease by age group

Age group	Apr-Jun 2011	12-months ending Jun 2011		12-months ending Jun 2010	
	Cases	Cases	Rate ^a	Cases	Rate ^a
<2 years	5	39	30.8	39	30.7
2-4 years	6	25	13.5	32	17.9
5-64 years	64	228	6.5	333	9.6
65+ years	60	233	40.9	231	41.8
Unknown	0	1	-	0	-
Total	135	526	12.0	635	14.7

^a Rate is expressed as cases per 100 000 population.

The distribution of IPD cases and rates by region is presented in Table 2. For the 12-month period ending 30 June 2011, the highest rate was reported in the Midland region (13.9 per 100 000 population, 116 cases). The Midland and Central regions had a significantly lower rate in the 12 months ending June 2011 compared to the previous 12-month period. There were no significant changes in rates in the Northern and Southern regions in the 12 months ending June 2011 compared to the previous 12 months.

Table 2. Number of cases and rates of invasive pneumococcal disease by region

Region	Apr-Jun 2011	12-months ending Jun 2011		12-months ending Jun 2010	
	Cases	Cases	Rate ^a	Cases	Rate ^a
Northern ^b	43	203	12.4	237	14.7
Midland ^c	38	116	13.9	155	18.8
Central ^d	26	100	10.0	139	14.0
Southern ^e	28	107	11.9	104	11.7
Total	135	526	12.0	635	14.7

^a Rate is expressed as cases per 100 000 population.

^b Includes Northland, Waitemata, Auckland, and Counties Manukau DHBs.

^c Includes Waikato, Lakes, Bay of Plenty, Tairāwhiti, and Taranaki DHBs.

^d Includes Hawke's Bay, Whanganui, MidCentral, Hutt Valley, Capital and Coast, Wairarapa, and Nelson Marlborough DHBs.

^e Includes West Coast, Canterbury, South Canterbury, and Southern DHBs.

Table 3 shows the culture-positive cases due to each of the serotypes included in PCV-7, PCV-10, and non-PCV-10 serotypes. Of the 135 cases notified in the April-June 2011 quarter, 119 (88.1%) were culture positive. The predominant PCV-7 serotype reported in the quarter was 19F (8 cases), occurring in the 2-4 years (3 cases) and 5+ years (5 cases) age groups. The predominant non-PCV serotype reported in this quarter were 3 (13 cases) and 19A (12 cases), mostly occurring in the 5+ years age groups.

Comparing the 12-month period ending 30 June 2011 with the previous 12 months, the number of cases due to each of the PCV-7 types decreased. Similarly, the number of cases due to serotype 1 (PCV-10, but not PCV-7, type), the most common serotype in both 12-month periods, decreased from 120 to 55 cases. However, the number of cases due to serotype 11A and 19A (non-PCV-10 types) increased by 8 and 13 cases respectively. Most of this increase occurred in the 5+ years age group.

Table 3. Number of invasive pneumococcal disease cases by serotype and age group

Serotypes	Age group											Total ^a	
	<2 years			2-4 years			5+ years			Total ^a			
	Q2 2011 ^b	2011 ^c	2010 ^d	Q2 2011 ^b	2011 ^c	2010 ^d	Q2 2011 ^b	2011 ^c	2010 ^d	Q2 2011 ^b	2011 ^c	2010 ^d	
4	0	0	1	0	2	0	7	39	58	7	41	59	
6B	0	1	1	0	0	5	4	19	23	4	20	29	
9V	0	1	0	0	1	1	5	24	31	5	26	32	
14	0	3	5	0	4	6	1	27	51	1	34	62	
18C	0	0	1	1	1	2	6	12	12	7	13	15	
19F	0	4	5	3	3	4	5	32	33	8	39	42	
23F	0	0	0	0	1	1	2	14	42	2	15	43	
Total (PCV-7)	0	9	13	4	12	19	30	167	250	34	188	282	
1	0	3	5	1	5	4	8	47	111	9	55	120	
5	0	0	0	0	0	0	0	0	1	0	0	1	
7F	0	2	1	0	0	0	3	10	11	3	12	12	
Total (PCV-10)	0	14	19	5	17	23	41	224	373	46	255	415	
3	0	1	3	0	2	0	13	26	25	13	29	28	
6A ^e	0	0	1	0	0	1	2	9	11	2	9	13	
9N	0	0	0	0	0	2	5	15	13	5	15	15	
11A	0	1	1	0	0	0	4	15	7	4	16	8	
19A	1	6	8	1	3	2	10	44	30	12	53	40	
22F	0	1	0	0	0	0	7	23	22	7	24	22	
Other types ^f	2	15	5	0	1	2	28	77	62	30	94	69	
Total (non-PCV-10)	3	24	18	1	6	7	69	209	170	73	240	195	

^a Total includes cases where age of case was unknown.

^b Cases reported in the second quarter of 2011 (April-June 2011).

^c Cases reported in the 12 months ending 30 June 2011.

^d Cases reported in the 12 months ending 30 June 2010.

^e Factorised sera to distinguish serotypes 6A and 6C was not used until 2010.

Therefore, some of the cases designated as serotype 6A in the 12 months ending 30 June 2010 may be 6C.

^f Other serotypes reported in the April-June 2011 quarter include 6C, 7A, 8, 10A, 11, 13, 17F, 18A, 20, 21, 22A, 23A, 31, 33F, 35, and 37.